Fundamental Analysis of CINGULATE INC(NASDAQ:CING) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to CING. CING was compared to 195 industry peers in the Pharmaceuticals industry. The financial health of CING is average, but there are quite some concerns on its profitability. CING does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CING has reported negative net income.

In the past year CING has reported a negative cash flow from operations.

In the past 5 years CING always reported negative net income.

CING had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -120.39%, CING is not doing good in the industry: 80.11% of the companies in the same industry are doing better.

CING has a worse Return On Equity (-135.81%) than 63.44% of its industry peers.

		Industry Rank	Sector Rank
ROA	-120.39%
ROE	-135.81%
ROIC	N/A

ROA(3y)-306.5%

ROA(5y)-252.45%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CING so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for CING has been reduced compared to 1 year ago.

The debt/assets ratio for CING is higher compared to a year ago.

2.2 Solvency

CING has an Altman-Z score of -7.86. This is a bad value and indicates that CING is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of CING (-7.86) is worse than 70.97% of its industry peers.

CING has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-7.86

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

CING has a Current Ratio of 7.35. This indicates that CING is financially healthy and has no problem in meeting its short term obligations.

With a decent Current ratio value of 7.35, CING is doing good in the industry, outperforming 76.34% of the companies in the same industry.

CING has a Quick Ratio of 7.35. This indicates that CING is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 7.35, CING is doing good in the industry, outperforming 77.42% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	7.35
Quick Ratio	7.35

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 72.80% over the past year.

EPS 1Y (TTM)72.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%97.46%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CING will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.98% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y97.55%

EPS Next 2Y41.06%

EPS Next 3Y25.91%

EPS Next 5Y14.98%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CING. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CING. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

CING's earnings are expected to grow with 25.91% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.06%

EPS Next 3Y25.91%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CING!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CINGULATE INC

NASDAQ:CING (1/15/2025, 12:26:32 PM)

4.88

+0.26 (+5.63%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-07 2024-11-07/bmo

Earnings (Next)N/A N/A

Inst Owners2.65%

Inst Owner Change0%

Ins Owners0.14%

Ins Owner Change-0.01%

Market Cap15.66M

Analysts80

Price Target61.46 (1159.43%)

Short Float %3.65%

Short Ratio0.61

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)14.5%

Min EPS beat(2)4.92%

Max EPS beat(2)24.09%

EPS beat(4)3

Avg EPS beat(4)6%

Min EPS beat(4)-54.52%

Max EPS beat(4)49.51%

EPS beat(8)4

Avg EPS beat(8)-2.81%

EPS beat(12)7

Avg EPS beat(12)-3.56%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-25%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-306.06%

EPS NY rev (1m)0%

EPS NY rev (3m)50.46%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.3
P/tB	1.3
EV/EBITDA	N/A

EPS(TTM)-106.42

EYN/A

EPS(NY)-3.96

Fwd EYN/A

FCF(TTM)-5.34

FCFYN/A

OCF(TTM)-5.28

OCFYN/A

SpS0

BVpS3.75

TBVpS3.75

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-120.39%
ROE	-135.81%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-306.5%

ROA(5y)-252.45%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	29.66%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.35
Quick Ratio	7.35
Altman-Z	-7.86

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)63.66%

Cap/Depr(5y)163.47%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)72.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%97.46%

EPS Next Y97.55%

EPS Next 2Y41.06%

EPS Next 3Y25.91%

EPS Next 5Y14.98%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y20.58%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-0.67%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-3.9%

OCF growth 3YN/A

OCF growth 5YN/A

CINGULATE INC (CING)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens